Türkiye’s Social Security Institution has revised the rules governing reimbursement for healthcare services and medicines. The amendment to the Health Implementation Communiqué, published in the Official Gazette dated October 2, 2026, under issue number 33388, covers organ and tissue transplants, selected cancer medicines, bone marrow transplant packages, surgical procedures for newborns and children, and treatment rules for a rare disease. A related decision by the Health Services Pricing Commission was published on the same day.
According to Labour and Social Security Minister Vedat Işıkhan, two medicines were added to the reimbursement system. One is used in early-stage breast cancer treatment, while the other is intended for a rare condition involving the optic nerve. The package also introduces reimbursement for certain advanced surgical procedures performed on newborn and pediatric patients. Reports based on the official text say that reimbursement conditions were defined for satralizumab and that the medicine was added to the relevant list under specified conditions of use.
The organ and tissue transplant section includes provisions intended to prevent interruptions in organ-preservation processes. The new rules revise how certain costs related to donors and the transfer of organs are handled as parts of the transplant pathway. The minister said the measures were designed to support continuity in organ-preservation protocols that are vital for patients awaiting transplantation. The practical details will be important for billing and documentation between hospitals and the Social Security Institution.
The amendment also changes bone marrow transplant packages and point values assigned to some medical procedures. The communiqué is the central reference used to determine which services are funded by the public insurance system, at what level, and under which conditions. Changes to points, packages and reimbursement lists therefore affect not only patients’ coverage but also the authorization and billing procedures used by public and private healthcare providers. The Turkish Pharmacists’ Association published the amendment and a comparative table for professional use.
The provisions do not all take effect on the same date. Independent reports citing the Official Gazette text say that the organ and tissue transplant clauses will be implemented 30 days after publication. Changes concerning cancer medicines, satralizumab and certain procedure points are scheduled to take effect after five working days. The bone marrow transplant package provision became effective on the publication date but applies from September 5, 2026. Other general clauses took effect on October 2.
This staggered schedule means patients and healthcare providers need to confirm which rules apply to a particular treatment and date. Inclusion of a medicine in the reimbursement system does not mean every use is automatically funded. The communiqué may set requirements concerning diagnosis, treatment stage, specialist reports, prescriptions and the type of healthcare institution. Patients should therefore rely on their physicians, pharmacists and the current authorization rules applied by the Social Security Institution for case-specific information.
The package addresses medicine lists, transplant logistics, pediatric surgery and procedure pricing together. It therefore reaches more than one stage of healthcare delivery, from treatment approval and hospital procedures to reimbursement. Healthcare institutions will need to align authorization and billing controls with the different implementation dates. Pharmacists and physicians will also need to check patient-specific eligibility against the current official wording rather than relying on a general announcement.
The measurable effect on access and hospital practice will become clearer as the implementation dates arrive and the rules are reflected in authorization systems and provider billing. For now, the communiqué in the Official Gazette, the Health Services Pricing Commission decision and the institution’s current implementation guidance remain the primary references. Any additional technical implementation guidance issued by the institution should also be monitored. This report explains the scope and timing of the regulatory change and is not individual medical advice.
